GlassScriptPhysician profile
Ramakrishna Battini
NPI 1710122601
$12,325.35
in general payments reported to CMS, 2019-2025
30 companies · $648 in 2025
The $648 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.38 · 2020: $3,910 · 2021: $1,682 · 2022: $1,478 · 2023: $4,255 · 2024: $336 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,028 · Food and Beverage: $1,081 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,027.50 |
| Food and Beverage | $1,081.14 |
| Education | $130.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,788.52 | 2020-2025 | Tagrisso, Imfinzi, Enhertu |
| Taiho Oncology, INC. | $1,868.65 | 2023-2025 | |
| Astrazeneca Uk Limited | $1,665.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $840.00 | 2023 | Darzalex |
| E.R. Squibb & Sons, L.L.C. | $125.44 | 2023-2025 | Opdivo, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $114.50 | 2025 | |
| Lilly USA, LLC | $102.31 | 2022-2024 | Jaypirca, Verzenio |
| Daiichi Sankyo INC. | $94.85 | 2025 | Enhertu |
| Eisai INC. | $78.52 | 2025 | |
| Pfizer INC. | $66.33 | 2024-2025 | |
| Emd Serono, INC. | $63.21 | 2022-2025 | Tepmetko |
| Novo Nordisk INC | $50.00 | 2024 | Wegovy |
| Astellas Pharma US INC | $47.34 | 2025 | Vyloy |
| Gilead Sciences, INC. | $46.30 | 2023-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $44.71 | 2021-2025 | Ninlaro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $35.56 | 2023-2025 | Blenrep |
| Merck Sharp & Dohme LLC | $34.35 | 2019-2025 | Keytruda, Welireg |
| Janssen Biotech, INC. | $33.74 | 2023-2025 | Talvey, Darzalex |
| Sumitomo Pharma America, INC. | $29.39 | 2025 | Orgovyx |
| Myovant Sciences INC. | $25.48 | 2022 | |
| Jazz Pharmaceuticals INC. | $23.28 | 2023 | Zepzelca |
| Incyte Corporation | $21.44 | 2024 | Jakafi |
| Amgen INC. | $21.27 | 2022 | |
| Sobi, INC | $20.75 | 2024 | |
| Celgene Corporation | $19.79 | 2025 | Reblozyl |
| Rigel Pharmaceuticals, INC. | $18.35 | 2024 | Rezlidhia, Tavalisse |
| Aveo Pharmaceuticals, INC. | $16.37 | 2024 | |
| Adaptive Biotechnologies Corporation | $15.07 | 2023 | Clonoseq |
| Seagen INC. | $14.83 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramakrishna Battini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.